These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 29157622

  • 1. Treatment of Idiopathic Castleman Disease.
    van Rhee F, Greenway A, Stone K.
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
    [Abstract] [Full Text] [Related]

  • 2. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC.
    Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
    [Abstract] [Full Text] [Related]

  • 3. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC.
    Hematology Am Soc Hematol Educ Program; 2018 Nov 30; 2018(1):318-325. PubMed ID: 30504327
    [Abstract] [Full Text] [Related]

  • 4. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K, Murayama S, Ito H, Koga T.
    Hematol Oncol Clin North Am; 2018 Feb 30; 32(1):23-36. PubMed ID: 29157617
    [Abstract] [Full Text] [Related]

  • 5. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.
    Blood; 2018 Nov 15; 132(20):2115-2124. PubMed ID: 30181172
    [Abstract] [Full Text] [Related]

  • 6. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC.
    Blood; 2018 Nov 29; 132(22):2323-2330. PubMed ID: 30487129
    [Abstract] [Full Text] [Related]

  • 7. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
    Ferrero S, Ragaini S.
    J Med Case Rep; 2021 Mar 07; 15(1):105. PubMed ID: 33676575
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
    Dong Y, Zhang L, Nong L, Wang L, Liang Z, Zhou D, Fajgenbaum DC, Ren H, Li J.
    Ann Hematol; 2018 Sep 07; 97(9):1641-1647. PubMed ID: 29732477
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
    Akiyama M, Yasuoka H, Takeuchi T.
    Ann Hematol; 2017 Dec 07; 96(12):2117-2119. PubMed ID: 28861599
    [No Abstract] [Full Text] [Related]

  • 10. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab.
    Tabata S, Higuchi T, Tatsukawa S, Narimatsu K, Takeo H, Matsukuma S, Ito T.
    Intern Med; 2019 Nov 15; 58(22):3313-3318. PubMed ID: 31292389
    [Abstract] [Full Text] [Related]

  • 11. The Cytokine Storm of Multicentric Castleman Disease.
    Fajgenbaum DC.
    Adv Exp Med Biol; 2024 Nov 15; 1448():459-467. PubMed ID: 39117833
    [Abstract] [Full Text] [Related]

  • 12. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
    Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, Mango N, Lavery C, Austin B, Alapat D, Lechowicz MJ, Bagg A, Li H, Casper C, van Rhee F, Fajgenbaum DC.
    Blood Adv; 2023 Nov 14; 7(21):6652-6664. PubMed ID: 37656441
    [Abstract] [Full Text] [Related]

  • 13. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H, Gong S, Remiker A, Rossoff J.
    Pediatr Blood Cancer; 2021 Oct 14; 68(10):e29261. PubMed ID: 34302703
    [Abstract] [Full Text] [Related]

  • 14. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L.
    Hematol Oncol; 2018 Feb 14; 36(1):320-323. PubMed ID: 28401573
    [Abstract] [Full Text] [Related]

  • 15. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z, Zeman D, Chodacki A, Pour L, Horváth T, Benda P, Adamová Z, Krejčí M, Tomíška M, Boichuk I, Král Z.
    Klin Onkol; 2023 Feb 14; 37(4):320-329. PubMed ID: 38195387
    [Abstract] [Full Text] [Related]

  • 16. Overview of Castleman disease.
    Dispenzieri A, Fajgenbaum DC.
    Blood; 2020 Apr 16; 135(16):1353-1364. PubMed ID: 32106302
    [Abstract] [Full Text] [Related]

  • 17. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
    Furutera N, Fukunaga N, Okita J, Suzuki T, Suenaga Y, Oyama Y, Aoki K, Fukuda A, Nakata T, Uesugi N, Daa T, Hisano S, Shibata H.
    CEN Case Rep; 2021 Feb 16; 10(1):35-41. PubMed ID: 32715375
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
    Lurain K, Yarchoan R, Uldrick TS.
    Hematol Oncol Clin North Am; 2018 Feb 16; 32(1):75-88. PubMed ID: 29157621
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
    van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R.
    Lancet Haematol; 2020 Mar 16; 7(3):e209-e217. PubMed ID: 32027862
    [Abstract] [Full Text] [Related]

  • 20. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
    Lang E, van Rhee F.
    Blood Rev; 2024 Mar 16; 64():101161. PubMed ID: 38087716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.